Ignite Creation Date:
2025-12-24 @ 11:55 AM
Ignite Modification Date:
2026-01-10 @ 4:18 PM
Study NCT ID:
NCT00621361
Status:
COMPLETED
Last Update Posted:
2012-12-17
First Post:
2008-02-12
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients
Sponsor:
AstraZeneca
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2008-02
Start Date Type:
None
Primary Completion Date:
2009-08
Primary Completion Date Type:
ACTUAL
Completion Date:
2012-02
Completion Date Type:
ACTUAL
First Submit Date:
2008-02-12
First Submit QC Date:
None
Study First Post Date:
2008-02-22
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2012-12-13
Last Update Post Date:
2012-12-17
Last Update Post Date Type:
ESTIMATED